2023年度肝癌治疗研究现状与问题  

Research status and problems of liver cancer treatment in 2023

作　　者：孙俪洋 潘扬勋 陈敏山[1] Sun Liyang;Pan Yangxun;Chen Minshan(Department of Liver Surgery,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心肝脏外科,广州510060

出　　处：《肿瘤综合治疗电子杂志》2024年第1期19-24,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：原发性肝癌是全球范围内最常见的恶性肿瘤之一,其中约85%为肝细胞癌(简称肝癌)。近年来国内外专家学者进行了大量的临床工作,提出了一系列有潜力的治疗药物和方案,有望进一步提高肝癌患者的疗效和长期生存。本文从外科围手术期治疗领域、系统药物治疗及多学科联合治疗3个大方向对2023年度肝癌治疗研究现状展开综述。Primary liver cancer is one of the most common malignances worldwide and hepatocellular carcinoma(HCC)represents about 85%.Recent years have witnessed extensive clinical trials by international experts and scholars,which yielding numerous promising drugs and therapeutic strategies for HCC,which are expected to further improve the efficiency andy long-term survival of patients.This paper summaries the progression of HCC treatment from the perspectives of perioperatively surgical interventions,systemic therapy,and multidisciplinary comprehensive treatment in 2023.

关 键 词：肝细胞癌 外科学 系统治疗 综合治疗 

分 类 号：R735.7[医药卫生—肿瘤]